Catalyst
Slingshot members are tracking this event:
Alkermes phase 1 study of ALKS-3831—which treats schizophrenia—testing antipsychotic efficacy versus placebo to be completed near end of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALKS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 26, 2018
Occurred Source:
https://www.prnewswire.com/news-releases/alkermes-completes-patient-enrollment-in-pivotal-weight-study-of-alks-3831-for-schizophrenia-300636663.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Alks 3831, Atypical Antipsychotic Drug Candidate, Phase 1, Schizophrenia, Olanzapine
